Suppr超能文献

基于药物基因组学的华法林剂量调整的临床应用。

Clinical applications of pharmacogenomics guided warfarin dosing.

机构信息

College of Pharmacy and Health Sciences, Drake University, 2507 University Ave, Des Moines, IA 50310, USA.

出版信息

Int J Clin Pharm. 2013 Jun;35(3):359-68. doi: 10.1007/s11096-010-9448-z. Epub 2010 Nov 4.

Abstract

AIM OF THE REVIEW

To assess the state of the literature concerning pharmacogenomic testing in patients requiring vitamin K antagonists, specifically warfarin.

METHOD

We conducted a literature search of MEDLINE and International Pharmaceutical Abstracts using the following words: warfarin, pharmacogenetic, and pharmacogenomic. The search results were reviewed by the authors and papers concerning pharmacogenomic testing in warfarin dosing were procured and reviewed. Additionally bibliographies of papers procured were also examined for other studies. The authors focused on clinical trials concerning the use of pharmacogenomic testing in warfarin dosing.

RESULTS

Although numerous studies have demonstrated that a significant portion of warfarin dosing variability can be explained by genetic polymorphisms, few prospective studies have been conducted that examine the integration of this information in practical dosing situations. Those that have, have shown that using pharmacogenomic information improves initial dosing estimates and decreases the need for frequent clinic visits and laboratory testing. Data showing a reduction in serious bleeding events is sparse. Cost-effectiveness analyses have generally shown a small but positive effect with pharmacogenomic testing in patients receiving warfarin.

CONCLUSION

Several studies have shown that pharmacogenomic testing for warfarin dosing is more accurate that other dosing schemes. Pharmacogenomic testing improves time to a therapeutic international normalized ratio while requiring fewer dosing adjustments. Patients who require higher or lower than usual doses seem to benefit the most. The cost-effectiveness of pharmacogenomic testing as well as preventing of outcomes such as bleeding or thrombosis are not yet elucidated. Pharmacists, especially those in a community setting can play a role in this new technology by educating prescribers and patients concerning pharmacogenomic testing, and by developing and using dosing protocols that incorporate its use.

摘要

目的

评估有关需要维生素 K 拮抗剂(尤其是华法林)的患者进行药物基因组检测的文献状况。

方法

我们使用以下关键词在 MEDLINE 和国际药学文摘中进行了文献检索:华法林、药物遗传学和药物基因组学。作者对检索结果进行了审查,并获取和审查了有关华法林剂量药物基因组检测的论文。此外,还检查了获取的论文的参考文献,以寻找其他研究。作者主要关注涉及药物基因组学检测在华法林剂量中的应用的临床试验。

结果

尽管许多研究表明,华法林剂量变异性的很大一部分可以用遗传多态性来解释,但很少有前瞻性研究检查将这一信息整合到实际剂量情况中。已经进行的研究表明,使用药物基因组学信息可以改善初始剂量估计,并减少频繁的诊所就诊和实验室检测的需要。显示严重出血事件减少的数据很少。成本效益分析通常表明,在接受华法林治疗的患者中,药物基因组学检测具有较小但积极的影响。

结论

几项研究表明,华法林剂量的药物基因组学检测比其他剂量方案更准确。药物基因组学检测可以提高达到治疗性国际标准化比值的时间,同时需要更少的剂量调整。需要高于或低于常规剂量的患者似乎受益最大。药物基因组学检测的成本效益以及预防出血或血栓形成等结果尚未阐明。药剂师,特别是那些在社区环境中的药剂师,可以通过教育处方者和患者有关药物基因组学检测的知识,并通过开发和使用包含其使用的剂量方案,在这项新技术中发挥作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验